GSK seeks US FDA blessing for GLP-1 albiglutide in Type II diabetes
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is seeking the US FDA's approval to market the London-based drug maker's experimental glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide as a once-weekly treatment for adults with Type II diabetes – revealing on 14 January that it had submitted a biologics license application (BLA) to the agency.